1. Pink Sheet
  2. >>Geography
  3. >>Europe

Coronavirus Notebook: Vaccine Pooling, WHO’s Law Lab & The Role Of The Llama

 
• By Ian Schofield

The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19. 

Covid19_Update
Progress is being made with potential COVID-19 vaccines and treatments • Source: Shutterstock

A further 75 higher-income countries have expressed interest in joining the Covax Global Vaccine Access Facility, a mechanism designed to ensure rapid and equitable access to COVID-19 vaccines as part of the global Access to COVID-19 Tools (ACT) Accelerator.

The Covax Facility, which was launched last month by the international vaccines alliance Gavi, includes an advance market commitment (AMC) that aims to generate a guaranteed volume of demand for vaccines before they are approved for use, giving manufacturers the incentive to invest in R&D and manufacturing capacity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

More from Geography

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.